MX366912B - Producción de vacuna recombinante en e. coli mediante conjugación enzimática. - Google Patents
Producción de vacuna recombinante en e. coli mediante conjugación enzimática.Info
- Publication number
- MX366912B MX366912B MX2015005797A MX2015005797A MX366912B MX 366912 B MX366912 B MX 366912B MX 2015005797 A MX2015005797 A MX 2015005797A MX 2015005797 A MX2015005797 A MX 2015005797A MX 366912 B MX366912 B MX 366912B
- Authority
- MX
- Mexico
- Prior art keywords
- coli
- production
- recombinant vaccine
- enzymatic conjugation
- glycoconjugates
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title 1
- 108010008038 Synthetic Vaccines Proteins 0.000 title 1
- 230000021615 conjugation Effects 0.000 title 1
- 230000002255 enzymatic effect Effects 0.000 title 1
- 229940124551 recombinant vaccine Drugs 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Una bacteria Gram-negativa diseñada para la producción de polisacárido, dicha bacteria Gram-negativa está caracterizada porque comprende (a) a un ácido nucleico que codifica un gen regular wzg, wzh, wzd o wze de ubn complejo génico de polisacárido capsular de S. pneumoniae CPS1, CPES2, CPS3, CPS4, CPS5, CPS6 (A y B) , CPS7 (A, B, C), CPS8, CPS9 (A, L, N, V, ), CPS10 (A, B, C, F,) CPS11 (A,B,C,D,F,) CPS12 (A, B,F) , CPS13, CPS14 CPS15 (A, B,C,F), CPS16 (A,F), CPS17 (A, F), CPS18 (A, B, F), CPS19 (A,B, C, F) CPS20, CPS21, CPS22 (A,F) CPS23 (A,B,F), CPS24 (A,B,F), CPS25 (A, F) CPS26, CPS27, CPS28 (A,F) CPS29, CPS31, CPS32 (A,F) CPS33 (A, B,C,D,F), CPS34, CPS35 (A, B,C,D,F,) CPS36, CPS37, CPS38, CPS39, CPS40, CPS41 (A,F)CPS42, CPS43, CPS44, CPS45, CPS46, CPS47 (A,F), o CPS48; o (b) un ácido nucleico que codifica un gen regulador capA, capB o capC de un complejo génico de polisacárido capsular de Staphylococcus auereus CPS5, o CPS8; o (c) un ácido nucleico que codifica un gen regulador CpsA, CpsB, CpsC o CpsD de un complejo génico de polisacárido capsular de Streptococcus agalactiae (grupo B, GBS) CPSIa, CPSlb, CPSII, CPSIII, CPSIV, CPSV, CPSVI, CPSVII, O CPSVIII, en donde la bacteria Gramj-negativa además comprende una oligosacaril-transferasa la cual es heterólogo para la bacteria Gram-negativa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| PCT/EP2013/073266 WO2014072405A1 (en) | 2012-11-07 | 2013-11-07 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005797A MX2015005797A (es) | 2016-03-09 |
| MX366912B true MX366912B (es) | 2019-07-30 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005797A MX366912B (es) | 2012-11-07 | 2013-11-07 | Producción de vacuna recombinante en e. coli mediante conjugación enzimática. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (es) |
| EP (3) | EP2917351B1 (es) |
| JP (2) | JP6412875B2 (es) |
| KR (1) | KR20150079964A (es) |
| CN (1) | CN105008539B (es) |
| AU (2) | AU2013343520B2 (es) |
| BR (1) | BR112015010283A8 (es) |
| CA (2) | CA3125293A1 (es) |
| EA (1) | EA201590705A1 (es) |
| ES (3) | ES2882282T3 (es) |
| IL (1) | IL238586A0 (es) |
| MX (1) | MX366912B (es) |
| SG (1) | SG11201503308XA (es) |
| TR (1) | TR201903066T4 (es) |
| WO (1) | WO2014072405A1 (es) |
| ZA (1) | ZA201503097B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102724997B (zh) * | 2009-11-19 | 2016-09-21 | 格林考瓦因有限公司 | 在原核细胞中产生免疫原性多糖的生物合成系统 |
| CA2926523C (en) * | 2013-10-11 | 2023-09-26 | Glycovaxyn Ag | Methods of host cell modification |
| JP6276427B2 (ja) | 2014-02-24 | 2018-02-07 | グリコヴァキシン アーゲー | 新規の多糖及びその使用 |
| HUE049806T2 (hu) * | 2014-04-17 | 2020-10-28 | Glaxosmithkline Biologicals Sa | Módosított gazdasejtek és alkalmazásaik |
| US10307474B2 (en) | 2014-08-08 | 2019-06-04 | Glaxosmithkline Biologicals S.A. | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| JP6764872B2 (ja) * | 2015-02-26 | 2020-10-07 | ヴァックスニューモ エルエルシーＶａｘｎｅｗｍｏ Ｌｌｃ | アシネトバクター（Ａｃｉｎｅｔｏｂａｃｔｅｒ）Ｏ−オリゴサッカリルトランスフェラーゼおよびその使用 |
| GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| WO2019090138A2 (en) * | 2017-11-04 | 2019-05-09 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Immunogenic conjugates and methods of use thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| CA3103474A1 (en) | 2018-06-16 | 2019-12-19 | Vaxnewmo Llc | Glycosylated comp pilin variants, methods of making and uses thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| CA3124312A1 (en) | 2018-12-21 | 2020-06-25 | Vaxnewmo Llc | O-linked glycosylation recognition motifs |
| EA202192392A1 (ru) * | 2019-03-18 | 2022-02-09 | Янссен Фармасьютикалз, Инк. | Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN112369722B (zh) * | 2020-05-08 | 2023-03-17 | 湖北中烟工业有限责任公司 | 加热不燃烧装置和温度控制方法 |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| EP4168040A1 (en) * | 2020-06-18 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Shigella-tetravalent (shigella4v) bioconjugate |
| CN115996749A (zh) | 2020-06-25 | 2023-04-21 | 葛兰素史克生物有限公司 | 经修饰的外毒素a蛋白 |
| PH12023550020A1 (en) | 2020-09-17 | 2024-03-11 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and uses thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995031548A1 (en) * | 1994-05-16 | 1995-11-23 | The Uab Research Foundation | Streptococcus pneumoniae capsular polysaccharide genes and flanking regions |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| PT1481057E (pt) | 2002-03-07 | 2006-05-31 | Eidgenoess Tech Hochschule | Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota |
| DK1888761T3 (da) | 2005-05-11 | 2010-11-01 | Eth Zuerich | Rekombinante N-glycosylerede proteiner fra prokaryote celler |
| LT2257307T (lt) | 2008-02-20 | 2018-08-10 | Glaxosmithkline Biologicals S.A. | Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių |
| JP5841044B2 (ja) * | 2009-03-23 | 2016-01-06 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 複合糖質ワクチン |
| EP2453762A4 (en) | 2009-07-17 | 2014-06-25 | Ocean Harvest Technology Canada Inc | NATURAL AND SUSTAINABLE ALGAE FORMULA THAT REPLACES SYNTHETIC ADDITIVES IN THE FEEDING OF SALMON |
| JP6339366B2 (ja) | 2010-05-06 | 2018-06-06 | グリコヴァキシン アーゲー | 莢膜グラム陽性菌のバイオコンジュゲートワクチン |
| ES2720040T3 (es) * | 2012-10-12 | 2019-07-17 | Glaxosmithkline Biologicals Sa | Procedimientos de modificación de células hospedadoras |
-
2013
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja not_active Expired - Fee Related
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en not_active Ceased
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Withdrawn
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh not_active Expired - Fee Related
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en not_active Ceased
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en not_active Ceased
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en not_active Expired - Fee Related
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015005797A (es) | Produccion de vacuna recombinante en e.coli mediante conjugacion enzimatica. | |
| ZA201601534B (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
| SG10201900948PA (en) | Modified nucleotide linkers | |
| MX2013004353A (es) | Produccion recombinante de n-propanol e isopropanol. | |
| MY191370A (en) | Production of odd chain fatty acid derivatives in recombinant microbial cells | |
| MX379386B (es) | Proceso de glicoconjugación. | |
| IN2014DN06104A (es) | ||
| EP4253395A3 (en) | Processes for the preparation of carbohydrate conjugated rna agents | |
| MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
| MX2014001383A (es) | Colageno 7 y metodos relacionados. | |
| SG10201809452RA (en) | Cell culture compositions with antioxidants and methods for polypeptide production | |
| MY182946A (en) | Production of organic acids by fermentation at low ph | |
| IN2012DN02210A (es) | ||
| MY180645A (en) | Microbial production of fatty amines | |
| IN2015DN03206A (es) | ||
| MX2011012623A (es) | Construcciones de casb7439. | |
| MX358132B (es) | Solucion de trombina y metodos de uso de esta. | |
| EP3456814A3 (en) | Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells | |
| IN2012DN02760A (es) | ||
| MX337070B (es) | Método para preparar un conjugado klh-egfrviii. | |
| MX2014007760A (es) | Bacterias con unidades transcripcionales reconstruidas y los usos de las mismas. | |
| MX2013005749A (es) | Composiciones y metodos para producir enterocinasa en levaduras. | |
| HK1210436A1 (en) | Novel cell compositions and methods | |
| WO2015117033A3 (en) | Methods of increasing protein production in mammalian cells | |
| GB2528604A (en) | Modulation of asymmetric proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. |
|
| FG | Grant or registration |